44P Potential combination of anti-CD-47 and natural compounds to harness calreticulin/CD47 immune checkpoint in triple-negative breast cancer patients

Advancements in cancer therapy have led to improved outcomes for many breast cancer subtypes. Yet, triple-negative breast cancer (TNBC) patients continue to face significant challenges, including chemo- and immuno-resistance. Calreticulin (CALR) is a pro-phagocytic surface marker necessary for calreticulin-mediated phagocytosis. However, as part of the immune evasion tactics of the cancer cells, a deregulated expression of CALR is evidenced in several malignancies and accompanied by induced elevation of the immune suppressive CD47 on cancer cells.